Clofibride
Clofibride is a lipid-lowering agent that was used in the past to manage hyperlipidemia, a condition characterized by elevated levels of lipids in the blood. It belongs to the class of drugs known as fibrates, which work by activating a specific receptor in the body known as the peroxisome proliferator-activated receptor alpha (PPARα). This activation leads to an increase in the oxidation of fatty acids, reduction of triglycerides, and an increase in high-density lipoprotein (HDL) levels, often referred to as "good cholesterol."
Mechanism of Action[edit | edit source]
Clofibride exerts its therapeutic effects by activating PPARα, a nuclear receptor that plays a crucial role in the metabolism of lipids. Upon activation, PPARα stimulates the expression of genes involved in the transport and breakdown of fatty acids in the liver, leading to decreased triglyceride levels and increased HDL cholesterol levels. This mechanism helps in reducing the risk of atherosclerosis and associated cardiovascular diseases.
Clinical Use[edit | edit source]
Historically, clofibride was used in the treatment of various forms of hyperlipidemia, particularly in cases where elevated triglyceride levels were a significant concern. However, its use has declined over the years, with newer and more effective lipid-lowering agents, such as statins and newer fibrates, taking precedence due to their improved efficacy and safety profiles.
Side Effects[edit | edit source]
Like other fibrates, clofibride could cause a range of side effects, including gastrointestinal disturbances, liver enzyme elevations, and myopathy. The risk of these adverse effects, particularly myopathy, increases when fibrates are used in combination with statins.
Current Status[edit | edit source]
As of the current medical and pharmaceutical landscape, clofibride is not widely used. The development of more effective lipid-lowering agents with better safety profiles has led to a decrease in the prescription of older fibrates like clofibride. Healthcare professionals now have a broader range of options for managing hyperlipidemia, allowing for more personalized and effective treatment plans.
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
